What Pfizer's FY2025 10-K says: 12 signals
Pfizer filed its latest 10-K with the SEC on Feb 26, 2026. It discusses restructuring, restructuring charge and acquisition completed.
Public (PFE)Pharmaceutical Manufacturing10,000+ employeespfizer.comLinkedIn
- Filed
- Feb 26, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What Pfizer's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Pfizer names 'Scale AI across our business' a key strategic priority for 2026.
As a top corporate priority for 2026, Pfizer is dedicating significant resources to scaling AI across R&D, manufacturing, and commercial operations.
AI
Pfizer executing enterprise-wide 'Realigning Our Cost Base Program' to cut costs.
The company is implementing a formal, named cost reduction program, which puts immense pressure on all departments to enhance efficiency.
The company is bracing for revenue and margin erosion due to increased competition and government pricing regulations like the IRA's Medicare negotiation program, making cost control and operational efficiency critical.
biosimilarsViatrisMylan
Pfizer launching major 2026 initiative to scale AI across the entire business.
Pfizer has identified 'Scale AI across our business' as one of its four key priorities for 2026.
AI
Pfizer completed acquisition of Metsera in November 2025, signaling a major integration effort.
The recent acquisition of Metsera requires the integration of business processes, data, and technology systems.
Pfizer implemented a major commercial reorganization effective January 1, 2026.
The creation of a new 'Global Hospital and Biosimilars' organization by realigning product portfolios disrupts existing sales, marketing, and reporting structures.
biosimilars
Pfizer focused on integrating recent acquisitions Metsera (Nov 2025) and Seagen (Dec 2023).
With 'Maximize value of key transactions' as a top 2026 priority, Pfizer is under pressure to harmonize the systems, data, and processes from its recent large acquisitions.
MetseraSeagenYaoPharma3SBio
Pfizer launched a 'Manufacturing Optimization Program' to reduce cost of goods sold.
This reorganization shifts product portfolios and responsibilities, which can disrupt existing workflows and create needs for new systems, processes, and reporting to support the new structure.
biosimilars
Pfizer highlights integration challenges following its Nov 2025 acquisition of Metsera.
Integrating newly acquired companies like Metsera presents significant operational, systems, and business process challenges, creating needs for consulting, systems integration, and change management services.
Metsera
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Pfizer with the Signal API
One POST /v1/companies/enrich call with pfizer.com returns Pfizer 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"pfizer.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Pfizer 10-K
When did Pfizer file its latest 10-K?
What does Pfizer's latest 10-K say about AI investment?
Where can I find Pfizer's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .